| Literature DB >> 27274631 |
Shanghun Shin1, Karam Kim1, Myung Joo Lee1, Jeongju Lee1, Sungjin Choi1, Kyung-Suk Kim1, Jung-Min Ko1, Hyunjoo Han1, Su Young Kim1, Hae Jeong Youn2, Kyu Joong Ahn2, In-Sook An3, Sungkwan An1, Hwa Jun Cha1.
Abstract
BACKGROUND: Dihydrotestosterone (DHT) induces androgenic alopecia by shortening the hair follicle growth phase, resulting in hair loss. We previously demonstrated how changes in the microRNA (miRNA) expression profile influenced DHT-mediated cell death, cell cycle arrest, cell viability, the generation of reactive oxygen species (ROS), and senescence. Protective effects against DHT have not, however, been elucidated at the genome level.Entities:
Keywords: Epigallocatechin gallate; Human dermal papilla cells; MicroRNAs
Year: 2016 PMID: 27274631 PMCID: PMC4884709 DOI: 10.5021/ad.2016.28.3.327
Source DB: PubMed Journal: Ann Dermatol ISSN: 1013-9087 Impact factor: 1.444
Fig. 1Effects of epigallocatechin gallate (EGCG) on human dermal papilla cell (DPC) viability and cell cycle progression. Human DPCs were treated with different concentrations of EGCG (A) or EGCG and dihydrotestosterone (DHT) (B) for 24 hours before water soluble tetrazolium salt (WST-1) assays to measure viability. (C) Human DPCs were treated with 10 µM EGCG or 10–4 M DHT for 24 hours before they were washed and stained with propidium iodide (PI; Sigma-Aldrich, St. Louis, MO, USA). The fluorescence intensity distributions of the stained cells were analyzed by flow cytometry (left) and the proportions of the cells in Sub-G1 phase were determined (right). Cells in the Sub-G1, G1, S, and G2/M phases were separated using the gates M1, M2, M3, and M4, respectively. Viability data are expressed as percentages of the viability of the internal control (untreated sample) and are shown as the mean±standard error of the mean of three independent experiments. #p<0.05 compared with vehicle, *p<0.05 compared with DHT.
Fig. 2Effects of epigallocatechin gallate (EGCG) on intracellular reactive oxygen species (ROS) levels and cellular senescence in human dermal papilla cells (DPCs). (A) Human DPCs were grown with or without 10 µM EGCG and 10–4 M dihydrotestosterone (DHT). To detect intracellular ROS levels, we performed 2',7'-dichlorofluorescein diacetate staining and detected cell cycle changes using a FACScalibur flow cytometer (BD Biosciences, San Jose, CA, USA). Changes in intracellular ROS levels were determined with the M1 gate. (B) Cells were treated with 10 µM EGCG or 10–4 M DHT for 48 hours. Senescence was measured using senescence- associated β-gal assays. Senescence data are expressed as percentages of the senescence of the internal control (untreated sample) and are shown as the mean±standard error of the mean of three independent experiments. PI: propidium iodide (Sigma-Aldrich, St. Louis, MO, USA). #p<0.05 compared with vehicle, *p<0.05 compared with DHT.
miRNAs from hDPCs with >2 fold expression change following EGCG and DHT treatment
| miRNA | Fold change | Direction of change to control | Chr | miRNA | Fold change | Direction of change to control | Chr |
|---|---|---|---|---|---|---|---|
| hsa-miR-181b | 2.17 | Up | chr1 | hsa-miR-17* | −82.18 | Down | chr13 |
| hsa-miR-181d | 137.76 | Up | chr19 | hsa-miR-1825 | −126.92 | Down | chr20 |
| hsa-miR-210 | 330.95 | Up | chr11 | hsa-miR-186 | −61.81 | Down | chr1 |
| hsa-miR-3656 | 2.26 | Up | chr11 | hsa-miR-188-5p | −147.60 | Down | chrX |
| hsa-miR-370 | 2.22 | Up | chr14 | hsa-miR-18b* | −56.14 | Down | chrX |
| hsa-miR-4257 | 66.47 | Up | chr1 | hsa-miR-202 | −47.66 | Down | chr10 |
| hsa-miR-4270 | 2.88 | Up | chr3 | hsa-miR-204 | −55.37 | Down | chr9 |
| hsa-miR-4271 | 2.17 | Up | chr3 | hsa-miR-28-5p | −49.61 | Down | chr3 |
| hsa-miR-4327 | 4.05 | Up | chr21 | hsa-miR-3180-5p | −53.64 | Down | chr16 |
| hsa-miR-590-5p | 147.55 | Up | chr7 | hsa-miR-324-5p | −49.46 | Down | chr17 |
| hsa-miR-629* | 140.42 | Up | chr15 | hsa-miR-33b* | −26.10 | Down | chr17 |
| hsa-miR-718 | 104.88 | Up | chrX | hsa-miR-3613-3p | −106.25 | Down | chr13 |
| hsa-miR-762 | 2.12 | Up | chr16 | hsa-miR-3676 | −135.08 | Down | chr17 |
| hsa-let-7a* | −38.70 | Down | chr9 | hsa-miR-369-3p | −49.41 | Down | chr14 |
| hsa-miR-100* | −51.87 | Down | chr11 | hsa-miR-3907 | −2.66 | Down | chr7 |
| hsa-miR-1225-3p | −2.00 | Down | chr16 | hsa-miR-411* | −29.26 | Down | chr14 |
| hsa-miR-1249 | −48.55 | Down | chr22 | hsa-miR-425* | −125.74 | Down | chr3 |
| hsa-miR-128 | −48.31 | Down | chr2 | hsa-miR-4306 | −121.68 | Down | chr13 |
| hsa-miR-1281 | −104.56 | Down | chr22 | hsa-miR-431 | −48.51 | Down | chr14 |
| hsa-miR-129-3p | −58.90 | Down | chr11 | hsa-miR-431* | −34.81 | Down | chr14 |
| hsa-miR-136 | −2.09 | Down | chr14 | hsa-miR-4317 | −52.71 | Down | chr18 |
| hsa-miR-138-2* | −71.90 | Down | chr16 | hsa-miR-550a | −25.75 | Down | chr7 |
| hsa-miR-146a | −49.51 | Down | chr5 | hsa-miR-664 | −140.38 | Down | chr1 |
| hsa-miR-150* | −54.57 | Down | chr19 | hsa-miR-766 | −2.38 | Down | chrX |
| hsa-miR-1539 | −55.61 | Down | chr18 | hsa-miR-770-5p | −77.43 | Down | chr14 |
| hsa-miR-16-2* | −26.03 | Down | chr3 | hsa-miR-933 | −31.12 | Down | chr2 |
miRNA: microRNA, hDPC: human dermal papillary cell, EGCG: epigallocatechin gallate, DHT: dihydrotestosterone, chr: chromosome.
Number of targets of selected miRNAs based on three prediction databases
| Targets of up-regulated miRNAs | Targets of down-regulated miRNAs | ||||
|---|---|---|---|---|---|
| Targetscan | PITA | microRNAorg | Targetscan | PITA | microRNAorg |
| 673 | 415 | 833 | 535 | 173 | 470 |
| Intersection of three target prediction databases: 306 | Intersection of three target prediction databases: 134 | ||||
TargetScan: http://www.targetscan.org, PITA: http://genie.weizmann.ac.il, microRNAorg: http://www.microrna.org, miRNAs: microRNAs.
Fig. 3Gene ontology classification of predicted target genes of microRNAs affected by epigallocatechin gallate in dihydrotestosterone-treated human dermal papilla cells. GO terms 1~5 are related to anti-oxidation: 1-oxidoreduction coenzyme metabolic process (GO:0006733); 2-response to oxidative stress (GO:0006979); 3-response to hydrogen peroxide (GO:0042542); 4-energy derivation by oxidation of organic compounds (GO:0015980); 5-oxidation reduction (GO:0055114). GO terms 6~22 are related to apoptosis and cell death: 6-anti-apoptosis (GO:0006916); 7-induction of apoptosis by extracellular signals (GO:0008624); 8-regulation of apoptosis (GO:0042981); 9-negative regulation of apoptosis (GO:0043066); 10-positive regulation of apoptosis (GO:0043065); 11-induction of apoptosis (GO:0006917); 12-apoptosis (GO:0006915); 13-regulation of programmed cell death (GO:0043067); 14-regulation of cell death (GO:0010941); 15-negative regulation of programmed cell death (GO:0043069); 16-negative regulation of cell death (GO:0060548); 17-positive regulation of programmed cell death (GO:0043068); 18-positive regulation of cell death (GO:0010942); 19-induction of programmed cell death (GO:0012502); 20-cell death (GO:0008219); 21-death (GO:0016265); 22-programmed cell death (GO:0012501). GO terms 23~33 are related to proliferation and cell growth: 23-cell proliferation (GO:0008283); 24-positive regulation of cell proliferation (GO:0008284); 25-regulation of cell proliferation (GO:0042127); 26-negative regulation of cell proliferation (GO:0008285); 27-negative regulation of cell growth (GO:0030308); 28-regulation of growth (GO:0040008); 29-regulation of developmental growth (GO:0048638); 30-negative regulation of growth (GO:0045926); 31-regulation of cell growth (GO:0001558); 32-positive regulation of growth (GO:0045927); 33-growth (GO:0040007). GO term 34 is related to aging (34-aging (GO:0007568). GO terms 35~48 are related to the cell cycle: 35-regulation of cell cycle (GO:0051726); 36-negative regulation of cell cycle (GO:0045786); 37-M phase of meiotic cell cycle (GO:0051327); 38-meiotic cell cycle (GO:0051321); 39-negative regulation of mitotic cell cycle (GO:0045930); 40-negative regulation of cell cycle process (GO:0010948); 41-regulation of mitotic cell cycle (GO:0007346); 42-cell cycle phase (GO:0022403); 43-regulation of cell cycle process (GO:0010564); 44-cell cycle (GO:0007049); 45-cell cycle process (GO:0022402); 46-mitotic cell cycle (GO:0000278); 47-cell cycle checkpoint (GO:0000075); 48-M phase of mitotic cell cycle (GO:0000087).